The diagnostic, prognostic, and therapeutic utility of molecular testing in a patient with Waldenstrom’s macroglobulinemia

Collin K. Chin, Connull Leslie, Carolyn S. Grove, Chris Van Vliet, Chan Yoon Cheah

Research output: Contribution to journalArticle

Abstract

The application of molecular genomics and our understanding of its clinical implications in the diagnosis, prognostication and treatment of lymphoproliferative disorders has rapidly evolved over the past few years. Of particular importance are indolent B-cell malignancies where tumour cell survival and proliferation are commonly driven by mutations involving the B-cell receptor and downstream signalling pathways. In addition, the increasing number of novel therapies and targeted agents have provided clinicians with new therapeutic options with the aim of exploiting such mutations. In this case report, we highlight one such success story involving the diagnostic impact of the MYD88L265P mutation inWaldenstrom’s macroglobulinemia (WM), its prognostic implications and effect on choice of therapy in the era of novel therapies.

Original languageEnglish
Article number2038
JournalInternational Journal of Molecular Sciences
Volume18
Issue number10
DOIs
Publication statusPublished - 1 Oct 2017

Fingerprint Dive into the research topics of 'The diagnostic, prognostic, and therapeutic utility of molecular testing in a patient with Waldenstrom’s macroglobulinemia'. Together they form a unique fingerprint.

  • Cite this